TNFSF11 and colitis: Additionally, Denosumab was recently found to reduce colonic expression of pro-inflammatory cytokines and modulate disruption of the microbiome in a murine model of colitis mimicking CD [161], suggesting a potential role for RANKL in disease pathogenesis.